In Vitro Study of the Bioavailability and Bioaccessibility of the Main Compounds Present in Ayahuasca Beverages

Joana Gonçalves 1,2, Miguel Castilho 1, Tiago Rosado 1,2, Ângelo Luís 1,2,*, José Restolho 1,*, Nicolás Fernández 3, Eugenia Gallardo 1,2,*,# and Ana Paula Duarte 1,2,*

1 Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; joanadgoncalves13@gmail.com (J.G.); miguel.castilho@ubi.pt (M.C.); tiagorosadofful@hotmail.com (T.R.); jrestolho@gmail.com (J.R.)
2 Laboratório de Farmacotoxicologia, UBMEDical, Universidade da Beira Interior, Estrada Municipal 506, 6200-284 Covilhã, Portugal
3 Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, Ciudad Autónoma de Buenos Aires (CABA), Buenos Aires C1113AAD, Argentina; nffernandez@fyb.uba.ar
* Correspondence: angelo.luis@ubi.pt (Â.L.); egallardo@fcs-udei.ubi.pt (E.G.); apcd@ubi.pt (A.P.D.);
Tel.: +351-275-329-003 (Â.L.& E.G.); +351-275-329-002 (A.P.D.)

Abstract: Ayahuasca is a psychoactive beverage that contains the psychoactive compound N,N-dimethyltryptamine and β-carboline alkaloids. This study aims at determining in vitro the bioavailability and bioaccessibility of the main compounds present in decoctions of four individual plants, in a commercial mixture and in four mixtures of two individual plants used in the preparation of Ayahuasca. The samples were subjected to an in vitro digestion process, and the Caco-2 cell line was used as an absorption model. The integrity and permeability of the cell monolayer were evaluated, as well as the cytotoxicity of the extracts. After digestion and cell incubation, the compounds absorbed by the cell monolayer were quantified by high-performance liquid chromatography coupled to a diode array detector. The results showed that compounds such as N,N-dimethyltryptamine, Harmine, Harmaline, Harmol, Harmalol and Tetrahydroharmine were released from the matrix during the in vitro digestion process, becoming bioaccessible. Similarly, some of these compounds, after being incubated with the cell monolayer, were absorbed, becoming bioavailable. The extracts did not show cytotoxicity after cell incubation, and the integrity and permeability of the cell monolayer were not compromised.

Keywords: ayahuasca; bioavailability; bioaccessibility; PAMPA; HPLC-DAD

1. Introduction

Ayahuasca is a psychoactive beverage traditionally consumed in the Amazon Basin of South America [1]. This word of Quecha origin, means “vine of the soul” or “vine of the dead” and is composed of the terms “aya” and “wasca”, which means “spirit” and “vine”, respectively [2,3]. This psychoactive beverage consists of a thick, oily and brownish decoction, which is prepared from the leaves of Psychotria viridis (P. viridis) and scrape stems from the stem of Banisteriopsis caapi (B. caapi) [4,5]. However, over the years, the preparation of Ayahuasca has undergone variations [1,2,6]. Thus, some species of natural origin have been used in the preparation of the beverage, namely Brunfelsia spp., Daturaolens, Malouetia tamarquina, Psychotria earthagensis, Brugmansia suaveolens, Tabernaemontana spp., or Nicotiana tabacum, replacing P. viridis, or Peganum harmala. Harmine freebase/HCl, Moclobemide and Tetrahydroharmine freebase/HCl, replacing B. caapi [6,7].

This psychoactive beverage was traditionally used by native healers for divine cults and in the cure of psychological disorders, stimulation of visual creativity and creative thinking [1,6]. Its hallucinogenic effects are due to the presence of N,N-dimethyltryptamine...
(DMT) (Figure 1) from \textit{P. viridis}, which behaves as an agonist of serotonin receptors (5-HT1A/2A/2C) \cite{3}. When ingested alone, this compound is inactive, as it is rapidly metabolized by peripheral monoamine oxidase A (MAO-A) \cite{8}. However, in the presence of $\beta$-carbolinic alkaloids, such as Harmaline, Harmine and Tetrahydroharmine (THH), from \textit{B. caapi}, DMT can access the central nervous system, since these are temporary inhibitors of hepatic and intestinal MAO-A \cite{2}. THH also acts as a serotonin reuptake inhibitor, enhancing the effects of DMT \cite{2,3}. The knowledge about this synergy between compounds present in the two plants has been known by indigenous peoples for about 3000 years \cite{9}.

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{molecule.png}
\caption{Molecular structure of DMT.}
\end{figure}

Although Ayahuasca has been consumed for centuries, in the last 25 years, its use has been increasing in different parts of the world \cite{10,11}. The consumption of Ayahuasca in controlled environments such as religious rituals and experimental procedures is not associated with psychotic episodes \cite{10}. However, the expansion of Ayahuasca has raised some concerns about the possible adverse effects associated with consumption, but also an interest in its potential therapeutic effects \cite{6,10}.

Bioavailability and bioaccessibility are important concepts that make it possible to understand the behaviour of some compounds in the body. Bioaccessibility consists of the amount of a compound that is released from a matrix, being available to be absorbed, after ingestion and consequent digestion \cite{12}. On the other hand, bioavailability is defined as the fraction that reaches the bloodstream and that, after metabolization and distribution, produces an effect \cite{13}. In vitro digestion is a procedure that has been used to determine the fraction of compounds that are released from the matrix and become bioaccessible \cite{14}. In vitro digestion models aim to mimic the digestive process along the digestive tract (mouth, stomach and intestine), simulating physiological conditions such as pH, salt concentration, digestion time, among others \cite{15,16}. Regarding the assessment of bioaccessibility, cell lines are frequently used, namely the line derived from a human colon carcinoma Caco-2, due to its similar morphology with the cells of the small intestine \cite{17}. In addition, these cells have narrow intracellular junctions and express enzymes similar to those that are present in the small intestine, allowing to mimic the transport mechanisms that occur therein \cite{18–20}.

There are no studies concerning the fate of the active ingredients of Ayahuasca formulations after ingestion, namely concerning their absorption to the general circulation for distribution. Therefore, with this study we aimed at evaluating the bioavailability and bioaccessibility of the active compounds present in four individual plants, a commercial mixture and four plant mixtures, used to prepare the Ayahuasca decoction. For that, an in vitro digestion process was used, as well as the parallel artificial membrane permeability assay (PAMPA) using Caco-2 cells, in order to know better their path in the human body and part of the mechanisms regulating their passage to the blood stream.

2. Results and Discussion

Considering the several potential bioactive properties of Ayahuasca, four individual decoctions of each plant used in the preparation of Ayahuasca were prepared in this work, as well as four decoctions of a mixture of plants (with two different plant materials, one source of DMT and the other of $\beta$-carboline alkaloids). A decoction of a commercial mixture
was also prepared. The bioavailability and bioaccessibility of the main compounds present in Ayahuasca was evaluated in the nine samples.

2.1. Characterization of Main Compounds in Initial Samples and after Digestive Process

DMT is present in some plants used in the preparation of Ayahuasca beverages. Given the use of plant samples containing this compound in religious rituals, it has received some attention over the years due to its psychoactive effects [21]. Besides that, the access of this compound to the bloodstream is dependent on the $\beta$-carboline alkaloids [1,8,22,23]. Thus, an analytical method by high performance liquid chromatography coupled diode array detector (HPLC-DAD) was developed, which allowed the quantification of the main active compounds present in the samples of Ayahuasca beverages (Table 1). This analytical method was developed and validated in accordance with the standards of the Food and Drug Administration [24]. Thus, it was linear between 0.16 and 10.00 $\mu$g/mL for Harmol, THH, Harmaline and Harmine, between 0.31 and 1.00 $\mu$g/mL for DMT, with coefficients of determination ($R^2$) higher than 0.997. The intra- and inter-day precision revealed coefficients of variation below 15% and the accuracy was within the range of ±15%. The LOD and LLOQ obtained were 0.31 $\mu$g/mL for all compounds, except for DMT (0.031 $\mu$g/mL).

All samples from a mixture of two plants showed substantial concentrations of DMT, with the mixture of $M$. hostilis and $B$. caapi having the highest concentration, and the mixture of $P$. viridis and $B$. caapi having the lowest concentration. Regarding the individual samples, both the $P$. viridis and $M$. hostilis decoctions and the commercial mixture showed substantial amounts of DMT. In contrast, in the decoctions of $B$. caapi and $P$. harmala, this compound was not detected. Moreover, all mixtures presented considerable concentrations of $\beta$-carboline alkaloids, with the mixture of $M$. hostilis and $P$. harmala presenting the highest amount. Regarding the individual samples, these compounds were not detected in the decoctions of $P$. viridis and $M$. hostilis. On the other hand, in the decoctions of $B$. caapi and $P$. harmala, all $\beta$-carboline alkaloids were detected, with THH and Harmol being in greater quantity in $B$. caapi and Harmine, Harmalol and Harmaline in greater quantity in $P$. harmala. Regarding the commercial mixture, it was possible to detect all $\beta$-carbines, except for Harmalol. Bensalem et al. [25] carried out the quantification of Harmine, Harmaline, Harmol and Harmalol in samples of $P$. harmala, having verified that, similarly to what was observed in the present study, the compound with the highest concentration was Harmaline, followed by Harmine, Harmalol and, the least concentrated, Harmol. In addition, Avula et al. [26] carried out the quantification of Harmol, Harmine, Harmaline, among other compounds, using ultra-performance liquid chromatography-triple quadrupole mass spectroscopy with ultraviolet detection (UPLC-UV-MS) and high-performance thin-layer chromatography (HPTLC). It was found that, similarly to the results now obtained, Harmine was found in a higher quantity than Harmol, being Harmaline not detected [26]. Several studies were also carried out, with the aim of determining the concentration of DMT and $\beta$-carbolines in Ayahuasca samples. Pires et al. [27] used gas chromatography equipment with nitrogen/phosphorous detector to quantify DMT, Harmine, Harmaline and THH in eight samples of Ayahuasca. Similar to what was observed in the present work, the four compounds were detected in all samples [27]. Moreover, Souza et al. [28] analysed 38 Ayahuasca samples using liquid chromatography coupled to tandem-mass spectrometry (LC-MS/MS) verified the presence of THH, DMT, Harmine and Harmaline. Recently, Chambers et al. [29] quantified the DMT present in 6 samples of Ayahuasca, obtaining values between 45.7 and 230.5 mg/L. It is important to point out that the concentrations of each compound in the Ayahuasca samples can be very variable. This fact can be due to a number of factors, namely the variability of the proportion used by each user, as well as the different preparation methods [27,28]. Additionally, the concentration of the compounds in each plant can also be very variable [27]. According to Kaasik et al. [30], the average variations of concentrations of DMT, THH, Harmine and Harmaline, can be,
respectively, 26.2%, 29.8%, 41.5% and 2.5%. The samples used in this study were acquired online, making it difficult to know their degree of purity.

Table 1. Concentration of the main compounds of ayahuasca in different vegetal samples. The values are expressed as mean (µg/mg extract) ± SD.

| Samples                  | Compounds | Initial Concentrations |
|--------------------------|-----------|------------------------|
| *P. viridis*             | DMT       | 6.50 ± 0.01            |
|                          | THH       | 5.00 ± 0.10            |
|                          | Harmol    | 0.14 ± 0.00            |
|                          | Harmine   | 10.00 ± 0.28           |
|                          | Harmalol  | 0.05 ± 0.00            |
|                          | Harmaline | 4.68 ± 0.14            |
| *B. caapi*               | THH       | 3.05 ± 0.04            |
|                          | Harmol    | 0.02 ± 0.00            |
| *P. harmala*             | THH       | 12.00 ± 0.00           |
|                          | Harmol    | 0.02 ± 0.00            |
|                          | Harmine   | 0.02 ± 0.00            |
|                          | Harmalol  | 0.05 ± 0.00            |
|                          | Harmaline | 0.37 ± 0.02            |
| *M. hostilis*            | DMT       | 10.50 ± 0.02           |
|                          | THH       | 10.40 ± 0.01           |
|                          | Harmol    | 0.01 ± 0.00            |
|                          | Harmine   | 0.02 ± 0.00            |
|                          | Harmalol  | ND                     |
|                          | Harmaline | 0.37 ± 0.02            |
| *P. viridis* + *B. caapi*| DMT       | 4.50 ± 0.01            |
|                          | THH       | 2.50 ± 0.07            |
|                          | Harmol    | 0.01 ± 0.00            |
|                          | Harmine   | 0.48 ± 0.00            |
|                          | Harmalol  | ND                     |
|                          | Harmaline | 0.07 ± 0.00            |
| *P. viridis* + *P. harmala* | DMT | 6.50 ± 0.09           |
|                          | THH       | 0.63 ± 0.05            |
|                          | Harmol    | 0.02 ± 0.00            |
|                          | Harmine   | 0.30 ± 0.01            |
|                          | Harmalol  | 0.08 ± 0.00            |
|                          | Harmaline | 0.48 ± 0.01            |
| *M. hostilis* + *B. caapi* | DMT | 8.00 ± 0.02           |
|                          | THH       | 1.90 ± 0.06            |
|                          | Harmol    | 0.03 ± 0.00            |
|                          | Harmine   | 0.82 ± 0.02            |
|                          | Harmalol  | 0.04 ± 0.00            |
|                          | Harmaline | 0.12 ± 0.00            |
| *M. hostilis* + *P. harmala* | DMT | 8.50 ± 0.01           |
|                          | THH       | 3.44 ± 0.05            |
|                          | Harmol    | 0.06 ± 0.00            |
|                          | Harmine   | 9.00 ± 0.00            |
|                          | Harmalol  | 0.36 ± 0.00            |
|                          | Harmaline | 13.5 ± 0.06            |

ND—not detected.

After quantifying the main compounds present in samples of Ayahuasca beverages, the same compounds were quantified over the three stages of the in vitro digestion process (salivary, gastric and duodenal). By observing the aliquots collected in each step, it is possible to verify that there were colour variations throughout the process. Likewise, the concentrations of DMT and β-carboline alkaloids also varied between samples and, within the same sample, between digestion steps (Table 2).
Table 2. Concentration of the main compounds of ayahuasca in different digestion steps. The values are expressed as mean (µg/mL) ± SD.

| Samples                  | Compounds | Salivary    | Gastric    | Duodenal   |
|--------------------------|-----------|-------------|------------|------------|
| P. viridis               | DMT       | 0.84 ± 0.60 | 7.77 ± 0.08| 7.49 ± 0.19|
|                          | THH       | 0.83 ± 0.00 | 0.78 ± 0.13| 1.05 ± 0.09|
|                          | Harmol    | ND          | ND         | ND         |
|                          | Harmine   | 1.56 ± 0.00 | 4.13 ± 0.03| 1.98 ± 0.03|
|                          | Harmalol  | ND          | ND         | ND         |
|                          | Harmaline | 0.19 ± 0.00 | 0.33 ± 0.00| 0.21 ± 0.00|
| B. caapi                 |           |             |            |            |
|                          | THH       | 1.52 ± 0.09 | 1.66 ± 0.12| 1.32 ± 0.01|
|                          | Harmol    | ND          | ND         | ND         |
|                          | Harmine   | 18.38 ± 0.18| 19.52 ± 0.05| 10.02 ± 0.01|
|                          | Harmalol  | 1.47 ± 0.04 | 1.54 ± 0.02| 1.93 ± 0.07|
|                          | Harmaline | 29.66 ± 0.10| 26.18 ± 0.14| 22.88 ± 0.26|
| P. harmala               |           |             |            |            |
|                          | THH       | 1.52 ± 0.09 | 1.66 ± 0.12| 1.32 ± 0.01|
|                          | Harmol    | ND          | ND         | ND         |
|                          | Harmine   | 18.38 ± 0.18| 19.52 ± 0.05| 10.02 ± 0.01|
|                          | Harmalol  | 1.47 ± 0.04 | 1.54 ± 0.02| 1.93 ± 0.07|
|                          | Harmaline | 29.66 ± 0.10| 26.18 ± 0.14| 22.88 ± 0.26|
| M. hostilis              | DMT       | 9.55 ± 0.03 | 8.96 ± 0.17| 8.33 ± 0.00|
|                          | THH       | 4.28 ± 0.05 | 4.09 ± 0.02| 3.38 ± 0.08|
|                          | Harmol    | ND          | ND         | ND         |
|                          | Harmine   | 1.64 ± 0.01 | 6.70 ± 0.12| 3.05 ± 0.10|
|                          | Harmalol  | 0.37 ± 0.01 | 0.38 ± 0.01| 0.34 ± 0.04|
|                          | Harmaline | 4.62 ± 0.02 | 8.93 ± 0.04| 4.05 ± 0.05|
| Commercial mixture       | DMT       | 2.37 ± 0.01 | 1.61 ± 0.05| 2.00 ± 0.02|
|                          | THH       | 3.33 ± 0.05 | 4.05 ± 0.11| 2.82 ± 0.02|
|                          | Harmol    | 0.29 ± 0.00 | 0.34 ± 0.00| 0.26 ± 0.01|
|                          | Harmine   | 1.23 ± 0.03 | 3.09 ± 0.22| 1.80 ± 0.05|
|                          | Harmalol  | 0.26 ± 0.00 | 0.27 ± 0.02| 0.25 ± 0.00|
|                          | Harmaline | 0.19 ± 0.01 | 0.40 ± 0.00| 0.26 ± 0.01|
| P. viridis + B. caapi    | DMT       | 4.30 ± 0.08 | 3.94 ± 0.13| 4.56 ± 0.15|
|                          | THH       | ND          | ND         | ND         |
|                          | Harmol    | ND          | ND         | ND         |
|                          | Harmine   | 1.64 ± 0.01 | 6.70 ± 0.12| 3.05 ± 0.10|
|                          | Harmalol  | 0.37 ± 0.01 | 0.38 ± 0.01| 0.34 ± 0.04|
|                          | Harmaline | 4.62 ± 0.02 | 8.93 ± 0.04| 4.05 ± 0.05|
| P. viridis + P. harmala  | DMT       | 9.07 ± 0.04 | 5.52 ± 0.09| 7.36 ± 0.05|
|                          | THH       | 2.89 ± 0.21 | 2.37 ± 0.11| 2.45 ± 0.04|
|                          | Harmol    | 0.28 ± 0.02 | 0.24 ± 0.01| 0.22 ± 0.00|
|                          | Harmine   | 4.02 ± 0.04 | 10.34 ± 0.07| 7.69 ± 0.27|
|                          | Harmalol  | ND          | ND         | ND         |
|                          | Harmaline | 0.28 ± 0.01 | 0.42 ± 0.01| 0.29 ± 0.01|
| M. hostilis + B. caapi   | DMT       | 9.07 ± 0.04 | 5.52 ± 0.09| 7.36 ± 0.05|
|                          | THH       | 2.89 ± 0.21 | 2.37 ± 0.11| 2.45 ± 0.04|
|                          | Harmol    | 0.28 ± 0.02 | 0.24 ± 0.01| 0.22 ± 0.00|
|                          | Harmine   | 4.02 ± 0.04 | 10.34 ± 0.07| 7.69 ± 0.27|
|                          | Harmalol  | ND          | ND         | ND         |
|                          | Harmaline | 0.28 ± 0.01 | 0.42 ± 0.01| 0.29 ± 0.01|
| M. hostilis + P. harmala | DMT       | 9.41 ± 0.07 | 10.92 ± 0.23| 9.38 ± 0.05|
|                          | THH       | 0.60 ± 0.03 | 0.87 ± 0.01| 0.63 ± 0.04|
|                          | Harmol    | ND          | ND         | ND         |
|                          | Harmine   | 4.11 ± 0.07 | 10.92 ± 0.23| 9.38 ± 0.05|
|                          | Harmalol  | 11.45 ± 0.20| 16.96 ± 0.11| 12.08 ± 0.02|
|                          | Harmaline | ND          | ND         | ND         |

ND—not detected.

Analysing the results, it was possible to verify that the amount of DMT varies throughout the in vitro digestion process. In general, the concentration of DMT at the end of the entire process decreased in samples of M. hostilis, in the commercial mixture and in the mixtures of M. hostilis and B. caapi and M. hostilis and P. harmala. Conversely, there was an increase in DMT in the sample of P. viridis, while in the mixtures of P. viridis and B. caapi and P. viridis and P. harmala there were no noticeable changes. With respect to β-carbolines, there was a variation from compound to compound. The concentration of Harmol remained constant throughout the digestion process of the sample of M. hostilis and B. caapi, increased in the mixture of P. viridis and B. caapi and was not detected in the other samples. It was
also not possible to detect Harmalol during the digestion of the samples of *B. caapi* and in the mixture of *M. hostilis* and *B. caapi*. In the other samples where this compound was initially detected, its concentration decreased slightly. Regarding THH, it was verified that its concentration increased in the samples of *B. caapi* and decreased in the commercial mixture and in mixtures of *P. viridis* and *B. caapi* and *M. hostilis* and *P. harmala*. A slight decrease of this compound was also observed in the sample of *P. harmala* and in the mixture of *M. hostilis* and *B. caapi*. In the mixture of *P. viridis* and *P. harmala* this compound was not detected. It was verified that the concentration of Harmine increased, except in the commercial mixture (not detected) and in *P. harmala* (decreased). The concentration of Harmaline remained constant in the mixture of *M. hostilis* and *B. caapi* and decreased in the sample of *P. harmala*, in the commercial mixture and in the mixture of *P. viridis* and *P. harmala*. In the samples of *B. caapi*, and in the mixtures of *P. viridis* and *B. caapi* and *M. hostilis* and *P. harmala*, there was a slight increase in the concentration of Harmaline. These variations in the concentrations of β-carboline alkaloids may be due to the fact that these compounds degrade and easily give rise to another β-carboline (Figure 2) [31].

![Figure 2. Reactions between β-carboline alkaloids.](image)

So far, no bioaccessibility studies have been carried out on Ayahuasca or plants used in its preparation. Digestion studies including this type of samples have not been carried out so far, so it is not possible to make a comparison.

2.2. Cell Culture
2.2.1. Evaluation of Cell Viability

The cytotoxicity of each sample was assessed using the MTT assay. In analysing the results, it was verified that there was a slight decrease in cell viability in the samples of the digested commercial mixture and in the crude extract of *B. caapi*. The other samples showed no decrease in cell viability (Table 3). These results are in agreement with those obtained by Katchborian-Neto et al. [32], which evaluated the cytotoxicity of Ayahuasca samples in SH-SY5Y cells. Additionally, three of the samples intensely increased cell viability within the first 48 h [32]. In addition, Samoylenko et al. [33] evaluated the cytotoxicity of *B. caapi* extracts in six cell lines, verifying that the extracts did not show cytotoxicity.
Table 3. Cell viability after exposure to extracts. The values are expressed as mean ± SD.

| Samples                     | Cell Viability (%) |
|-----------------------------|--------------------|
| *P. viridis* Crude          | 156.01 ± 27.31     |
| *P. viridis* Digested       | 128.85 ± 9.03      |
| *B. caapi* Crude            | 95.92 ± 1.83       |
| *B. caapi* Digested         | 113.66 ± 11.59     |
| *P. harmala* Crude          | 171.46 ± 28.88     |
| *P. harmala* Digested       | 117.62 ± 3.59      |
| *M. hostilis* Crude         | 148.28 ± 14.18     |
| *M. hostilis* Digested      | 96.04 ± 12.23      |
| Commercial mixture Crude    | 101.50 ± 13.25     |
| Commercial mixture Digested | 79.52 ± 0.93       |
| *P. viridis* + *B. caapi* Crude | 148.07 ± 26.83 |
| *P. viridis* + *B. caapi* Digested | 103.74 ± 3.43 |
| *P. viridis* + *P. harmala* Crude | 162.55 ± 15.63 |
| *P. viridis* + *P. harmala* Digested | 127.75 ± 9.97 |
| *M. hostilis* + *B. caapi* Crude | 138.41 ± 17.63 |
| *M. hostilis* + *B. caapi* Digested | 120.70 ± 3.12 |
| 2.2.2. Evaluation of the Electrical Resistance of the Cell Transendothelial Membrane

The integrity of the cell monolayer was evaluated by the TEER assay, before and after cell incubation with the extracts (Table 4). The TEER assay allows monitoring the integrity of cell layers in in vitro assays, as well as possible changes in intercellular junctions, by evaluating transendothelial electrical resistance [34]. Analysing the results of the TEER measurements before incubation with the extracts, it was observed that the monolayer was intact, since the values were above the 150–200 Ω cm² range, minimum acceptable limit [35]. After incubation with the extracts, a new TEER measurement was performed, with no significant differences between the values of the first and second measurements. Additionally, the values of the second measurement were also above the minimum acceptable limit. Therefore, the integrity of the cell monolayer was confirmed [35]. So far, there are no studies with Ayahuasca samples where the TEER assay has been performed.

Table 4. TEER values obtained before and after incubation with the extracts. The values are expressed as mean ± SD. Statistically significant values were considered if *p* < 0.05 (*).
2.2.3. Evaluation of Cell Monolayer Permeability

Cell monolayer permeability was assessed by Lucifer Yellow permeability assay (Table 5). The Lucifer Yellow permeability assay allows evaluating the permeability characteristics of a cell monolayer, by measuring the passive diffusion of different molecules through it [36]. This assay was performed after exposing the cells to extracts. Analysing the results, it was shown that there were no significant changes in cell permeability, when compared to the control. These results are in agreement with those obtained in the TEER assay, suggesting that there were no changes in intracellular spaces, nor in cell barrier function and in membrane permeability [37,38]. Previous studies also suggest that both TEER measurement and permeability are related, and that a significant increase in the permeability is accompanied by a decrease in TEER values [37,38]. Similarly to what was observed in the TEER assay, no studies were found where the Lucifer Yellow permeability assay was performed with Ayahuasca samples.

Table 5. Percentage of permeability of Caco-2 cells after incubation with the extracts. The values are expressed as mean ± SD. Statistically significant values were considered if \( p < 0.05 \) (*).

| Samples                     | Permeability (%) | \( p \)-Value |
|-----------------------------|-----------------|--------------|
| Control                     | 16.94 ± 2.35    | -            |
| \( P. \ viridis \) Crude    | 19.59 ± 3.00    | 0.281        |
| \( P. \ viridis \) Digested | 13.49 ± 1.03    | 0.165        |
| \( B. \ caapi \) Crude      | 16.79 ± 0.14    | 0.879        |
| \( B. \ caapi \) Digested  | 16.11 ± 0.49    | 0.823        |
| \( P. \ harmala \) Crude   | 15.01 ± 0.46    | 0.462        |
| \( P. \ harmala \) Digested| 17.97 ± 1.37    | 0.523        |
| \( M. \ hostilis \) Crude  | 14.38 ± 0.72    | 0.322        |
| \( M. \ hostilis \) Digested | 14.10 ± 0.41   | 0.267        |
| Commercial mixture Crude    | 19.88 ± 2.84    | 0.383        |
| Commercial mixture Digested | 16.13 ± 1.83    | 0.865        |
| \( P. \ viridis + B. \ caapi \) Crude | 16.42 ± 0.40 | 0.959        |
| \( P. \ viridis + B. \ caapi \) Digested | 16.03 ± 1.50 | 0.463        |
| \( P. \ viridis + P. \ harmala \) Crude | 13.81 ± 0.49 | 0.225        |
| \( P. \ viridis + P. \ harmala \) Digested | 13.47 ± 1.85 | 0.283        |
| \( M. \ hostilis + B. \ caapi \) Crude   | 13.07 ± 1.89    | 0.139        |
| \( M. \ hostilis + B. \ caapi \) Digested | 13.18 ± 0.16   | 0.074        |
| \( M. \ hostilis + P. \ harmala \) Crude | 12.40 ± 1.64  | 0.069        |
| \( M. \ hostilis + P. \ harmala \) Digested | 11.65 ± 1.79    | 0.058        |

2.2.4. Characterization of the Main Compounds after Cell Incubation

The amount of compounds present in the collected aliquots after cell incubation of crude and digested extracts were also quantified by HPLC-DAD (Tables 6 and 7). It was verified that DMT, Harmine and Harmaline are the compounds, from those present in the digested extract, which cross the cell monolayer the most. Similarly, in the crude extract the same results were observed. The concentration of these three compounds in all samples and for both extracts, increased gradually in the basolateral compartment throughout the incubation period, except in the digested extract in the mixture of \( P. \ viridis \) and \( B. \ caapi \), where DMT increases after 2 h of incubation, remaining approximately constant until 4 h of cell incubation. In general, in the digested extract, all the compounds gradually increased during cell incubation, except for Harmol and Harmalol, which were not detected during the entire process. Similarly, in the crude extract, Harmalol was not detected, but Harmol was detected after 2 h of incubation in the \( P. \ harmala \) sample. Moreover, as in what was observed in the digested extract, in the crude extract all compounds gradually increased during cell incubation, except for the THH present in the mixture of \( M. \ hostilis \) and \( B. \ caapi \), which decreases slightly after 2 h of incubation, increasing again after 4 h.
Table 6. Concentration of the main compounds of Ayahuasca in the aliquots collected after the different incubation times with the crude extract (Mean µg/mL Extract) ± SD.

| Samples          | Compounds | Time          | 1 h   | 2 h   | 4 h   |
|------------------|-----------|---------------|-------|-------|-------|
| P. viridis       | DMT       | 0.50 ± 0.01   | 0.89 ± 0.21 | 1.22 ± 0.05 |
|                  | THH       | ND            | 0.66 ± 0.02 | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | 0.33 ± 0.03   | 1.00 ± 0.01 | 1.35 ± 0.03 |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| B. caapi         | DMT       | 0.89 ± 0.21   | ND     | ND    |
|                  | THH       | ND            | 0.19 ± 0.02 | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | 2.09 ± 0.02   | 4.41 ± 0.23 | 5.90 ± 0.04 |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| P. harmala       | DMT       | ND            | 0.55 ± 0.04 | ND    |
|                  | THH       | ND            | ND     | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | ND            | 0.72 ± 0.12 | ND    |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| M. hostilis      | DMT       | ND            | 0.73 ± 0.04 | ND    |
|                  | THH       | ND            | ND     | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | ND            | ND     | ND    |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| Commercial mixture | DMT     | 0.55 ± 0.04   | 0.73 ± 0.04 | ND    |
|                  | THH       | ND            | ND     | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | ND            | ND     | ND    |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| P. viridis + B. caapi | DMT | 0.16 ± 0.01   | 0.47 ± 0.06 | 0.63 ± 0.07 |
|                  | THH       | 0.65 ± 0.02   | 0.78 ± 0.06 | 0.93 ± 0.04 |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | ND            | 0.76 ± 0.06 | ND    |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| P. viridis + P. harmala | DMT | 0.33 ± 0.03   | 1.01 ± 0.16 | 1.10 ± 0.07 |
|                  | THH       | ND            | ND     | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | 0.35 ± 0.02   | 0.39 ± 0.01 | 0.78 ± 0.04 |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | 0.31 ± 0.00   | 0.67 ± 0.09 | 0.76 ± 0.03 |
| M. hostilis + B. caapi | DMT | 0.69 ± 0.07   | 1.67 ± 0.11 | 1.87 ± 0.04 |
|                  | THH       | 0.74 ± 0.08   | 0.53 ± 0.03 | 0.65 ± 0.07 |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | 0.98 ± 0.11   | 1.64 ± 0.11 | 2.42 ± 0.08 |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | ND            | ND     | ND    |
| M. hostilis + P. harmala | DMT | 0.29 ± 0.01   | 0.72 ± 0.04 | 1.24 ± 0.18 |
|                  | THH       | ND            | ND     | ND    |
|                  | Harmol    | ND            | ND     | ND    |
|                  | Harmanine | 0.47 ± 0.02   | 1.07 ± 0.10 | 1.63 ± 0.27 |
|                  | Harmalol  | ND            | ND     | ND    |
|                  | Harmaline | 0.55 ± 0.08   | 1.07 ± 0.14 | 1.42 ± 0.22 |

ND = not detected.
Table 7. Concentration of the main compounds of Ayahuasca in the aliquots collected after the different incubation times with the digested extract (Mean µg/mL) ± SD.

| Samples            | Compounds | Time     |
|--------------------|-----------|----------|
|                    |           | 1 h      | 2 h      | 4 h      |
| P. viridis         | DMT       | 0.73 ± 0.00 | 1.48 ± 0.02 | 1.99 ± 0.03 |
|                    | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | ND       | ND       | 1.14 ± 0.03 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | ND       | ND       | ND       |
| B. caapi           | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | 1.83 ± 0.01 | 3.08 ± 0.09 | 4.19 ± 0.03 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | 3.81 ± 0.13 | 4.75 ± 0.12 | 5.63 ± 0.08 |
| P. harmala         | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | 3.81 ± 0.00 | 4.75 ± 0.12 | 5.63 ± 0.08 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | ND       | ND       | ND       |
| M. hostilis        | DMT       | ND       | 1.61 ± 0.07 | 1.90 ± 0.02 |
| Commercial mixture | DMT       | ND       | 0.61 ± 0.02 | 0.67 ± 0.02 |
|                    | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | ND       | ND       | ND       |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | ND       | ND       | ND       |
| P. viridis + B. caapi | DMT     | ND       | 0.50 ± 0.07 | 0.48 ± 0.01 |
|                    | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | ND       | ND       | 0.70 ± 0.02 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | ND       | ND       | ND       |
| P. viridis + P. harmala | DMT   | ND       | 0.65 ± 0.00 | 0.86 ± 0.03 |
|                    | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | ND       | 1.02 ± 0.01 | 1.26 ± 0.03 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | 0.74 ± 0.00 | 0.99 ± 0.01 | 1.26 ± 0.01 |
| M. hostilis + B. caapi | DMT   | 0.78 ± 0.01 | 1.74 ± 0.01 | 2.11 ± 0.02 |
|                    | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | 0.77 ± 0.00 | 1.96 ± 0.01 | 2.54 ± 0.64 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | ND       | ND       | ND       |
| M. hostilis + P. harmala | DMT   | 0.60 ± 0.03 | 1.57 ± 0.06 | 1.86 ± 0.02 |
|                    | THH       | ND       | ND       | ND       |
|                    | Harmol    | ND       | ND       | ND       |
|                    | Harmin    | 0.85 ± 0.03 | 2.38 ± 0.09 | 3.34 ± 0.04 |
|                    | Harmalol  | ND       | ND       | ND       |
|                    | Harmaline | 1.10 ± 0.02 | 2.21 ± 0.01 | 3.02 ± 0.03 |

ND-not detected.

In general, it was possible to observe that all the analysed compounds managed to cross the cell monolayer, except Harmalol and Harmol. In the digested samples the bioavailability percentages ranged between 8.30–28.9% for DMT, 0–29.63% for Harmaline and 33.03–57.58% for Harmin. So far, no studies have been carried out on the bioavailability of Ayahuasca, so it is not possible to make comparisons with the present study. However, differences in β-carboline concentrations can be explained by the rapid mutual conversion of these compounds (Figure 2) [31]. Additionally, DMT easily crosses the barriers of the body, since it is a small and hydrophobic molecule with a low molecular weight [21]. It was
also observed that the amount of the compounds decreased after crossing the cell monolayer, when compared to the values obtained after in vitro digestion. This fact has already been verified in bioavailability studies with other compounds of natural origin [39,40]. In a study that evaluated the bioavailability and bioaccessibility of *Prunus avium* L., carried out by our research group, this same decrease in the amount of compounds after crossing the Caco-2 cell monolayer was also verified [14].

3. Materials and Methods

3.1. Chemicals and Materials

The analytical standards DMT, Harmaine, Harmaline, THH, Harmol and Harmalol were kindly provided by Nal von Minden, GmbH (Regensburg, Germany). Lucifer Yellow, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and Roswell Park Memorial Institute (RPMI) medium were obtained from Sigma-Aldrich (Sintra, Portugal). Methanol (HPLC grade) was obtained from Fischer Chemical (Loughborough, UK). Formic acid and dimethyl sulfoxide (99.9% of purity) were purchased from Sigma-Aldrich (Sintra, Portugal). Deionized water was obtained from a Milli-Q System (Millipore, Billerica, MA, USA).

3.2. Sample and Working Solutions Preparation

All vegetal samples were acquired online from Shayana Shop (https://www.shayanashop.com, Amsterdam, The Netherlands) (accessed on 25 May 2019). The decoctions of Ayahuasca were prepared according to a traditional recipe kindly provided by Dr. Nicolás Fernández. Thus, 0.210 g of each of the five vegetal samples were weighed (*P. viridis* (leaves), *P. harmala* (seeds), *B. caapi* (scrap from the stem), *M. hostilis* (root bark) and commercial mixture) and were then macerated in a mortar with a few drops of water. After that, 250 mL of ultra-pure water was added, and the mixture was transferred to a Schott flask. This preparation was boiled at 100 °C for 4 h. Similarly, four decoctions were prepared where two of the above vegetal samples were mixed (*P. viridis* and *P. harmala*; *P. viridis* and *B. caapi*; *M. hostilis* and *P. harmala*; *M. hostilis* and *B. caapi*). After boiling, the samples were cooled, filtered, frozen at −80 °C and freeze-dried.

Individual stock solutions of DMT, Harmaine, Harmaline, Harmol and Harmalol were prepared at 1 mg/mL in methanol. Working solutions were prepared by serial dilutions in methanol.

3.3. In Vitro Simulation of Human Digestion Process

The in vitro digestion assay was carried out as described in a previous work [14]. Initially, salivary fluid (potassium chloride, monosodium phosphate, sodium sulphate, sodium chloride, sodium bicarbonate, urea, α-amylase, mucin and uric acid), gastric fluid (sodium chloride, monosodium phosphate, potassium chloride, calcium chloride, ammonium chloride, hydrochloric acid, glucose, urea, pepsin, mucin and bovine serum albumin), duodenal fluid (sodium chloride, sodium bicarbonate, potassium dihydrogen phosphate, potassium chloride, magnesium chloride, hydrochloric acid, urea, calcium chloride dihydrate, bovine serum albumin, pancreatin and lipase) and bile fluid (sodium chloride, sodium bicarbonate, potassium chloride, hydrochloric acid, urea, calcium chloride dihydrate, bile and bovine serum albumin) were prepared. For the assay, each freeze-dried decoction was dissolved in 100 mL of deionized water. To each of the nine samples, 6 mL of simulated salivary fluid (pH 6.8) was added, being this mixture was incubated at 37 °C for 5 min with orbital shaking at 90 rpm. Then, 12 mL of simulated gastric fluid (pH 1.3) was added, followed by incubation in the same conditions for 2 h. After this time, 6 mL of simulated bile fluid (pH 8.2), 12 mL of simulated duodenal fluid (pH 8.1) and 2 mL of sodium bicarbonate solution (1M) was added. The solution was incubated again at 37 °C with orbital shaking at 90 rpm for 2 h.

Aliquots were collected at the end of each stage of the in vitro digestion process, which were immediately cooled, then frozen at −80 °C for 30 min and later sonicated at 4 °C in
an ice bath for 30 min. Subsequently, the samples were filtered through a 0.22 \mu m cellulose acetate pore filter and subsequently analysed by high-performance liquid chromatography (HPLC). Furthermore, an additional aliquot of the last stage of the in vitro digestion of each sample was collected, which was also placed on ice, frozen at \(-80\) °C and sonicated. Then, their pH was measured and corrected, when necessary, to physiological pH. Subsequently, these aliquots were used in the PAMPA assay.

3.4. Cell Culture

The Caco-2 cell line (Database name: American Type Culture Collection (ATCC) Accession numbers: HTB-37\cite{41}) was cultured in RPMI medium supplemented with 1% antibiotic mixture and 10% foetal bovine serum, at passages between 33 and 37. Subsequently, the cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2.

For the MTT assay, the cells were seeded in 96 multi-well plates (cat. number 734-2802 avantor, VWR, Amadora Portugal) at a cell density of \(0.5 \times 10^4\). For the PAMPA assay, the cells were seeded in culture inserts, placed in 12 multi-well plates (cat. number 734-2731 avantor, Laborspirit, Santo Antão de Tojal, Portugal) at a cell density of \(6 \times 10^4\), remaining for a period of 21 days in order to form a confluent monolayer. After that time, 500 \mu L of each of the nine samples (digested and undigested) was added to the apical chamber, to be in contact with the cell monolayer (\(P. viridis\)—0.278 mg/mL; \(B. caapi\)—0.062 mg/mL; \(P. harmala\)—0.226 mg/mL; \(M. hostilis\)—0.382 mg/mL; commercial mixture—0.344 mg/mL; \(M. hostilis + B. caapi\)—0.555 mg/mL e \(M. hostilis + P. harmala\)—0.4 mg/mL). After 1, 2 and 4 h, 250 \mu L was collected in the basolateral chamber. The collected aliquots were analysed by HPLC. All tests were performed in triplicate.

3.4.1. MTT Cell Viability Assay

The cytotoxicity of the samples was assessed by the MTT assay. For that, after the cells became confluent, they were exposed to the samples (digested and undigested) 1, 2 and 4 h. RPMI medium was used as a negative control. After incubation, the medium was removed and an MTT solution was added. Then, the cells were incubated for 3 h. After that time, the MTT solution was removed, and the formazan crystals formed were dissolved in dimethyl sulfoxide (DMSO), being the absorbance measured using a microplate reader at 570 nm.

3.4.2. Transepithelial Electrical Resistance Assay

The integrity of the cell monolayer was evaluated by measuring the transepithelial electrical resistance (TEER). Before the incubation of the cells’ monolayer with the extracts (digested and undigested), the TEER was measured. Initially, the electrode of the transepithelial resistance meter (EVOM2, World Precision Instrument, Sarasota, FL, USA) was equilibrated with RPMI medium and then was placed in each well to form an angle of 90°. The procedure was performed in triplicate and the TEER was determined according to the following equation:

\[
\text{TEER value} = (\text{mean of the resistances of each well} - \text{mean of the resistance of blank}) \times \text{insert area} \tag{1}
\]

3.4.3. Lucifer Yellow Permeability Assay

The Lucifer Yellow Permeability Assay allows evaluating changes in the permeability characteristics of the cell monolayer after passive passage of compounds. This test was performed as described in a previous work \cite{14}. Briefly, the RPMI medium of the chambers delimited by the insert (apical and basolateral) was removed and replaced by 500 \mu L of the Lucifer Yellow solution in the apical chamber and 1.5 mL of Hank’s balanced salt solution (HBSS) in the basolateral chamber. After that, the multi-well was incubated for 1 h, and then 200 \mu L of each basolateral chamber was pipetted to another culture plate, being the fluorescence measured at 485 nm (excitation) and 535 nm (emission) using a
spectrofluorimeter. HBSS was used as a blank and a Lucifer Yellow solution (0.1 mg/mL) was used as a positive control. The permeability percentage was calculated as follows:

\[
\% \text{permeability} = \frac{\text{mean of fluorescence of each well} - \text{fluorescence of blank}}{\text{fluorescence of positive control} - \text{fluorescence of blank}} \times 100
\]  

(2)

3.5. Instrumental and Chromatographic Conditions

The quantification of main compounds present in Ayahuasca beverages was performed on an HPLC system coupled to a diode array detector (DAD) (Agilent technologies Soquímica, Lisbon, Portugal). The mobile phase was composed of 0.1% formic acid in methanol (A) and 0.1% formic acid in water (B). The elution was carried out in gradient mode and included 5% A (0–2 min), 50% A (2–32 min) and again, 5% A (32–40 min). The flow rate was 1.5 mL/min, and the injection volume was 50 µL. The stationary phase consisted of an YMC-Triart PFP (5 µm, 4.6 i.d. × 150 mm) analytical column coupled to a Guard-c holder (4 × 10 mm) and a Triart PFP (5 µm, 3 ×10 mm) pre-column, all from YMC Europe GMBH (Solítica, Lisbon, Portugal), being maintained at 25 °C. Harmine and Harmol were detected at 246 nm, DMT and THH at 278 nm and Harmaline and Harmalol at 360 nm. The temperature of the sampler was set at 4 °C.

3.6. Statistical Analysis

The results are expressed as mean values with standard deviations (SD). The Student’s t-test was employed and statistically significant values were considered when \( p < 0.05 \) (*).

4. Conclusions

During the in vitro digestion, the compounds were released from the matrix, becoming bioaccessible. The concentration of β-carboline alkaloids shows an appreciable transformation, while the variation of DMT is smaller. After the in vitro digestion, the detected compounds could be absorbed by the cell monolayer, becoming bioavailable but in lower concentrations. Likewise, the compounds present in the extracts that did not undergo in vitro digestion also became bioavailable. So, it can be inferred that digestion is not essential to occur absorption at the intestine level.

After cell incubation with the extracts, it was verified that they were not cytotoxic, and the integrity and the permeability of the cell monolayer remained unchanged, suggesting that the compounds did not interfere with intercellular junctions.

Further studies in which a more realistic approximation of the intestinal matrix is used should be carried out in order to overcome possible flaws of the used model.

Author Contributions: Conceptualization, Â.L., E.G. and A.P.D.; plant materials, J.R.; sample preparation, N.F.; methodology, J.G. and T.R.; chromatographic analysis and data, M.C. and T.R.; formal analysis, J.G.; investigation, J.G.; writing—original draft preparation, J.G.; writing—review and editing, J.G., Â.L., E.G. and A.P.D.; supervision, Â.L., E.G. and A.P.D.; funding acquisition, Â.L., J.R., E.G. and A.P.D. All authors have read and agreed to the published version of the manuscript.

Funding: This work was partially supported by CICS-UBI, which is financed by National Funds from Fundação para a Ciência e a Tecnologia (FCT) and by Fundo Europeu de Desenvolvimento Regional (FEDER) under the scope of PORTUGAL 2020 and Programa Operacional do Centro (CENTRO 2020), with the project reference UIDB/00709/2020. Joana Gonçalves acknowledges the PhD fellowship from FCT (Reference: SFRH/BD/149360/2019). Ângelo Luís acknowledges the contract of Scientific Employment in the scientific area of Microbiology financed by FCT.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding authors.

Conflicts of Interest: The authors declare no conflict of interest.
Sample Availability: Not available.

References

1. Estrella-Parra, E.A.; Almanza-Pérez, J.C.; Alarcón-Aguilar, F.J. Ayahuasca: Uses, Phytochemical and Biological Activities. *Nat. Prod. Bioprospect.* 2019, 9, 251–265. [CrossRef]

2. Hamill, J.; Hallak, J.; Dursun, S.M.; Baker, G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. *Curr. Neuropsychopharmacol.* 2018, 17, 108–128. [CrossRef] [PubMed]

3. Gonçalves, J.; Luis, Â.; Gradillas, A.; Garcia, A.; Restolho, J.; Fernández, N.; Domingues, F.; Gallardo, E.; Duarte, A.P. Ayahuasca beverages: Phytochemical analysis and biological properties. *Antibiotics* 2020, 9, 731. [CrossRef] [PubMed]

4. Andrade, T.S.; de Oliveira, R.; da Silva, M.L.; Von Zuben, M.V.; Grisolia, C.K.; Domingues, I.; Calsdas, E.D.; Pic-Taylor, A. Exposure to ayahuasca induces developmental and behavioral alterations on early life stages of zebrafish. *Chem. Biol. Interact.* 2018, 293, 133–140. [CrossRef] [PubMed]

5. Gable, R.S. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. *Addiction* 2007, 102, 24–34. [CrossRef]

6. Gonçalves, J.; Luis, Â.; Gradillas, A.; Garcia, A.; Restolho, J.; Fernández, N.; Domingues, F.; Gallardo, E.; Duarte, A.P. Ayahuasca beverages: Phytochemical analysis and biological properties. *Antibiotics* 2020, 9, 731. [CrossRef] [PubMed]

7. Simão, A.Y.; Gonçalves, J.; Duarte, A.P.; Barroso, M.; Cristóvão, A.C.; Gallardo, E. Toxicological Aspects and Determination of the Main Components of Ayahuasca: A Critical Review. *Medicines* 2019, 6, 106. [CrossRef]

8. Riba, J.; Valle, M.; Urbano, G.; Yritia, M.; Morte, A.; Barbanoj, M.J. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. *J. Pharmacol. Exp. Ther.* 2003, 306, 73–83. [CrossRef]

9. Callaway, J.C.; McKenna, D.J.; Grob, C.S.; Brito, G.S.; Raymon, L.P.; Poland, R.E.; Andrade, E.N.; Andrade, E.O.; Mash, D.C. Pharmacokinetics of Hoasca alkaloids in healthy humans. *J. Ethnopharmacol.* 1999, 65, 243–256. [CrossRef]

10. dos Santos, R.G.; Bouso, J.C.; Hallak, J.E.C. Ayahuasca, dimethyltryptamine, and psychosis: A systematic review of human studies. *Ther. Adv. Psychopharmacol.* 2017, 7, 141–157. [CrossRef]

11. Gaujac, A.; Dempster, N.; Navickiene, S.; Brandt, S.D.; De Andrade, J.B. Determination of N,N-dimethyltryptamine in beverages consumed in religious practices by headspace solid-phase microextraction followed by gas chromatography ion trap mass spectrometry. *Talanta* 2013, 106, 394–398. [CrossRef]

12. Li, Y.; Padoan, E.; Ajроме-Marson, F. Soil particle size fraction and potentially toxic elements bioaccessibility: A review. *Ecotoxicol. Environ. Saf.* 2021, 209, 111806. [CrossRef] [PubMed]

13. Carbonell-Capella, J.M.; Buniewska, M.; Barba, F.J.; Esteve, M.J.; Frigola, A. Analytical methods for determining bioavailability and bioaccessibility of bioactive compounds from fruits and vegetables: A review. *Compr. Rev. Food Sci. Food Saf.* 2014, 13, 155–171. [CrossRef] [PubMed]

14. Gonçalves, J.; Ramos, R.; Luis, Â.; Rocha, S.; Rosado, T.; Gallardo, E.; Duarte, A.P. Assessment of the Bioaccessibility and Bioavailability of the Phenolic Compounds of Prunus avium L. by in Vitro Digestion and Cell Model. *ACS Omega* 2019, 4, 7605–7613. [CrossRef]

15. Versantvoort, C.H.M.; Oomen, A.G.; Van De Kamp, E.; Rempelberg, C.J.M.; Sips, A.J.A.M. Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food. *Food Chem. Toxicol.* 2005, 43, 31–40. [CrossRef]

16. Minekus, M.; Alminger, M.; Alvito, P.; BALLANCE, S.; Bohn, T.; Bourlieu, C.; Carrió, I.; Barbanoj, M.J. Identification of bioaccessible and uptaken phenolic compounds from strawberry fruits in in vitro digestion/Caco-2 absorption model. *Food Funct.* 2014, 5, 1113–1124. [CrossRef] [PubMed]

17. Sambuy, Y.; De Angelis, I.; Ranaldi, G.; Scarino, M.L.; Stammati, A.; Zuoco, F. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. *Cell Biol. Toxicol.* 2005, 21, 1–26. [CrossRef] [PubMed]

18. Barthé, L.; Woodley, J.; Hourin, G. Gastrointestinal absorption of drugs: Methods and studies. *Fundam. Clin. Pharmacol.* 1999, 13, 154–168. [CrossRef] [PubMed]

19. Kosiriska-Cagnazzo, A.; Diering, S.; Prim, D.; Andlauer, W. Identification of bioaccessible and uptaken phenolic compounds from strawberry fruits in in vitro digestion/Caco-2 absorption model. *Food Chem.* 2015, 170, 288–294. [CrossRef]

20. Devkar, S.; Kandhare, A.; Sloley, B.; Jagtap, S.; Lin, J.; Tam, Y.; Katyare, S.; Bodhankar, S.; Hegde, M. Evaluation of the bioavailability of major withanolides of Withania somnifera using an in vitro absorption model system. *J. Adv. Pharm. Technol. Res.* 2015, 6, 159–164. [CrossRef]

21. Cameron, L.P.; Olson, D.E. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT). *ACS Chem. Neurosci.* 2018, 9, 2344–2357. [CrossRef]

22. Riba, J.; Romero, S.; Grasa, E.; Mena, E.; Carrió, I.; Barbanoj, M.J. Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant. *Psychopharmacology* 2006, 186, 93–98. [CrossRef] [PubMed]

23. De Araújo, D.B.; Ribeiro, S.; Cecchi, G.A.; Carvalho, F.M.; Sanchez, T.A.; Pinto, J.P.; de Martinis, B.S.; Crippa, J.A.; Hallak, J.E.C.; Santos, A.C. Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. *Hum. Brain Mapp.* 2012, 33, 2550–2560. [CrossRef] [PubMed]
24. Food and Drug Administration Bioanalytical Method Validation Guidance for Industry. Available online: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs (accessed on 9 June 2021).

25. Bensalem, S.; Soubhye, J.; Aldib, I.; Bourinel, L.; Nguyen, A.T.; Vanhaeverbeek, M.; Rousseau, A.; Boudjeltia, K.Z.; Sarakbi, A.; Kauffmann, J.M.; et al. Inhibition of myeloperoxidase activity by the alkaloids of *Peganum harmala* L. (Zygophyllaceae). *J. Ethnopharmacol.* 2014, 154, 361–369. [CrossRef] [PubMed]

26. Avula, B.; Wang, Y.H.; Rumalla, C.S.; Smillie, T.J.; Khan, I.A. Simultaneous determination of alkaloids and flavonoids from aerial parts of *Passiflora* species and dietary supplements using UPLC-UV-MS and HPTLC. *Nat. Prod. Commun.* 2012, 7, 1177–1180. [CrossRef]

27. Pires, A.P.S.; De Oliveira, C.D.R.; Moura, S.; Dörri, F.A.; Silva, W.A.E.; Yonamine, M. Gas chromatographic analysis of dimethyltryptamine and β-carboline alkaloids in Ayahuasca, an amazonian psychoactive plant beverage. *Phytochem. Anal.* 2009, 20, 149–153. [CrossRef]

28. Souza, R.C.Z.; Zandonadi, F.S.; Freitas, D.P.; Tófoli, L.F.F.; Sussulini, A. Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2019, 1124, 197–203. [CrossRef]

29. Chambers, M.L.; Appley, M.G.; Longo, C.M.; Musah, R.A. Detection and Quantification of Psychoactive N, N-Dimethyltryptamine in Ayahuasca Brews by Ambient Ionization High-Resolution Mass Spectrometry. *ACS Omega* 2020, 5, 28547–28554. [CrossRef]

30. Kaasik, H.; Souza, R.C.Z.; Zandonadi, F.S.; Tófoli, L.F.; Sussulini, A. Chemical Composition of Traditional and Analog Ayahuasca. *J. Psychoact. Drugs* 2021, 53, 65–75. [CrossRef]

31. Taylor, W.I. Simple Derivatives Of Tryptophan. In *Indole Alkaloids*; Taylor, W.I., Ed.; Pergamon Press, Elsevier: Amsterdam, The Netherlands, 1966; Volume 1, pp. 29–51. ISBN 9781483196718.

32. Katchborian-Neto, A.; Santos, W.T.; Nicádio, K.J.; Corrêa, J.O.A.; Murgu, M.; Martins, T.M.M.; Gomes, D.A.; Goes, A.M.; Soares, M.G.; Dias, D.F.; et al. Neuroprotective potential of Ayahuasca and untargeted metabolomics analyses: Applicability to Parkinson’s disease. *J. Ethnopharmacol.* 2020, 255, 112743. [CrossRef]

33. Samoylenko, V.; Rahman, M.M.; Tekwani, B.L.; Tripathi, L.M.; Wang, Y.H.; Khan, S.I.; Khan, I.A.; Miller, L.S.; Joshi, V.C.; Muhammad, I. Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease. *J. Ethnopharmacol.* 2010, 127, 357–367. [CrossRef] [PubMed]

34. Elbrecht, D.H.; Long, C.J.; Hickman, J.J. Transepithelial/endothelial Electrical Resistance (TEER) theory and applications for blood-brain barrier penetration models. *Eur. J. Pharm. Biopharm.* 2012, 82, 340–351. [CrossRef] [PubMed]

35. Hellinger, E.; Veszelka, S.; Tóth, A.E.; Walter, F.; Kittel, A.; Bakk, M.L.; Tihaný, K.; Háda, V.; Nakagawa, S.; Dinh Ha Duy, T.; et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. *Eur. J. Pharm. Biopharm.* 2012, 82, 340–351. [CrossRef] [PubMed]

36. Colombini, A.; Perego, S.; Ardoino, I.; Marasco, E.; Lombardi, G.; Fiorilli, A.; Biganzoli, E.; Tettamanti, G.; Ferrarotto, E. Evaluation of a possible direct effect by casein phosphopeptides on paracellular and vitamin D controlled transcellular calcium transport mechanisms in intestinal human HT-29 and Caco2 cell lines. *Food Funct.* 2013, 4, 1195–1203. [CrossRef] [PubMed]

37. Satsu, H.; Yokoyama, T.; Ogawa, N.; Fujiwara-Hatano, Y.; Shimizu, M. The changes in the neuronal PC12 and the intestinal epithelial Caco-2 cells during the coculture. The functional analysis using an in vitro coculture system. *Cytotechnology* 2001, 35, 73–79. [CrossRef] [PubMed]

38. Fazzari, M.; Fukumoto, L.; Mazza, G.; Livrea, M.A.; Tesoriere, L.; Di Marco, L. In vitro bioavailability of phenolic compounds from five cultivars of fresh and processed cherries (Prunus avium L.). *J. Agric. Food Chem.* 2007, 56, 3561–3458. [CrossRef]

39. Toydemir, G.; Boyacıoğlu, D.; Çapanoğlu, E.; Van Der Meer, I.M.; Tomassen, M.M.M.; Hall, R.D.; Mes, J.J.; Beekwilder, J. Investigating the transport dynamics of anthocyanins from unprocessed fruit and processed fruit juice from sour cherry (Prunus cerasus L.) across intestinal epithelial cells. *J. Agric. Food Chem.* 2013, 61, 11434–11441. [CrossRef] [PubMed]

40. ATCC Caco-2 [Caco2] | ATCC. Available online: https://www.atcc.org/products/htb-37 (accessed on 2 September 2021).